TSC1 and plasma cell myeloma: Despite the occurrence of TSC, targeting the inhibitionof the TSC2 complex holds significant potential for advancing drugdevelopment efforts aimed at treating multiple myeloma (MM) becausemultiple myeloma (MM) is a life-threatening malignancy with an urgentneed for immediate and aggressive treatment.